Should Research Subjects Be Given Their Genetic Test Results?
By Margaret Lutze,
Guardian Liberty Voice
| 06. 12. 2014
Untitled Document
Should research subjects be given their genetic test results? A paper recently published in The American Journal of Human Genetics considered the ethical issues related to returning genetic testing results to people who have participated in research experiments.
There is a growing number of research projects that use next-generation DNA sequencing to determine the sequence of the DNA nucleotides (ATCGs) in a person’s entire genome. Next-generation sequencing is a new technique that allows DNA sequencing information for an individual to be gathered very quickly. Previously, only certain chosen areas of a person’s genome would be sequenced for a research study due to time and efficiency constraints. Now, however, with the efficiency of next-generation sequencing, it is cost- and time-effective to sequence everything, meaning all the DNA of that person.
The ethical dilemma that results from this is the fact that the research scientist now has information about all of the research subject’s genes, and there may be something in their genetic make-up that would be medically significant for that person. The question is, since the research scientist may now have...
Related Articles
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Staff, GMWatch | 03.28.2026
Following a recent podcast interview we were asked whether there is any solid scientific research looking at how gene expression or molecular composition in genetically modified (GM) plants differs from conventionally bred plants. As this is an interesting and important...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...